At the close of the recent quarter, Celsion Corp. (NASDAQ:CLSN)‘s balance sheet demonstrated total assets worth $30.8M and debt of 1.47M%. Compared to the previous period, the debt increased/decreased by growing.
Celsion Corp.’s total liabilities closing the latest quarter was $24.69M.
Let’s look into the technical of the stock
The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction. Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend. The market is in highly oversold territory. Beware of a trend reversal.
The assets that the firm listed at the close of the recent quarter comprised cash balance of 4.47M%. Net operating cash from the previous quarter was $(3.13M), resulting in free cash flow of $(3.15M). Compared to the previous period, net change in case was $1.85M.
The cash that Celsion Corp. generated in the previous quarter stemmed from sales of $125,000.
After considering other operating expenses, the firm closed with a net income figure. When that amount divided by the number of outstanding shares it closed up with EPS (earnings per share) of $(1.68). For perspective on how Celsion Corp. reached at the EPS figure, shareholders should know that the firm closed the last quarter with diluted due shares of 3.03M.
Wall Street analysts reported investors should anticipate from Celsion Corp. EPS of $-0.73 in the next quarter.
In addition to estimating the next quarter’s EPS, market analysts have weighed in on the stock of Celsion Corp. regarding whether shareholders should view it as a SELL, BUY or HOLD. Some 3 analysts have analyzed the stock so far, giving it an average recommendation of Overweight.
Celsion Corporation (NASDAQ:CLSN), an oncology drug development company, today announced that it received notice from The NASDAQ Stock Market LLC (NASDAQ) on June 13, 2017 indicating that the Company has regained compliance with the minimum bid price requirement under NASDAQ Listing Rule 5550(a)(2) for continued listing on The NASDAQ Capital Market. Accordingly, Celsion is in compliance with all applicable listing standards and its common stock will continue to be listed on The NASDAQ Capital Market and NASDAQ considers the matter closed.